Patents by Inventor Mary Elizabeth HARTNETT

Mary Elizabeth HARTNETT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220347318
    Abstract: Disclosed are nucleic acid constructs comprising a nucleic acid sequence encoding a vitelliform macular dystrophy-2 (VMD2) promoter operably linked to a nucleic acid sequence encoding Rap1a. Disclosed are vectors comprising the nucleic acid constructs disclosed herein. Disclosed are compositions comprising the disclosed nucleic acid constructs or vectors. Also disclosed are methods of treating a subject having age-related macular degeneration comprising administering one or more of the disclosed nucleic acid constructs, vectors, or compositions to a subject in need thereof.
    Type: Application
    Filed: September 25, 2020
    Publication date: November 3, 2022
    Inventors: Mary Elizabeth Hartnett, Haibo Wang, William Hauswirth, Vince Chiodo
  • Patent number: 10214741
    Abstract: Disclosed are vectors and compositions comprising a pol II promoter and an shRNA wherein the shRNA has a sense RNA strand and an antisense RNA strand, wherein the sense and the antisense RNA strands form an RNA duplex, and wherein the sense RNA strand comprises a nucleotide sequence identical to a target sequence in STAT3, VEGFR, or EPOR. Also disclosed are methods of treating retinopathy of prematurity (ROP), methods of inhibiting expression of STAT3, VEGFR, and EPOR, and methods of regulating signaling events associated with intravitreal neovascularization (IVNV).
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: February 26, 2019
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventor: Mary Elizabeth Hartnett
  • Publication number: 20170051280
    Abstract: Disclosed are vectors and compositions comprising a pol II promoter and an shRNA wherein the shRNA has a sense RNA strand and an antisense RNA strand, wherein the sense and the antisense RNA strands form an RNA duplex, and wherein the sense RNA strand comprises a nucleotide sequence identical to a target sequence in STAT3, VEGFR, or EPOR. Also disclosed are methods of treating retinopathy of prematurity (ROP), methods of inhibiting expression of STAT3, VEGFR, and EPOR, and methods of regulating signaling events associated with intravitreal neovascularization (IVNV).
    Type: Application
    Filed: February 13, 2015
    Publication date: February 23, 2017
    Inventor: Mary Elizabeth HARTNETT
  • Patent number: 5912414
    Abstract: Four chimeric genes are disclosed. A first chimeric gene encoding a plant cystathionine .gamma.-synthase (CS), a second chimeric gene encoding feedback-insensitive aspartokinase, which is operably linked to a plant chloroplast transit sequence, a third chimeric gene encoding bifunctional feedback-insensitive aspartokinase-homoserine dehydrogenase (AK-HDH), which is operably linked to a plant chloroplast transit sequence, and a fourth chimeric gene encoding a methionine-rich protein, all operably linked to plant seed-specific regulatory sequences are discussed. Methods for their use to produce increased levels of methionine in the seeds of transformed plants are provided.
    Type: Grant
    Filed: November 8, 1996
    Date of Patent: June 15, 1999
    Assignee: E. I. du Pont de Nemours and Company
    Inventors: Saverio Carl Falco, Anthony Dominick Guida, Jr., Mary Elizabeth Hartnett Locke